PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
Rhea-AI Summary
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has scheduled its Q1 2025 financial results announcement for May 14, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time.
Key highlights:
- Conference participants are advised to register 5 minutes before the call
- The company's core technology, PLEX (Polymer-Lipid Encapsulation matriX), enables controlled drug release over extended periods
- Their lead product, D-PLEX100, is in Phase 3 trials for preventing abdominal colorectal surgical site infections
- A preclinical candidate, OncoPLEX, is being tested for solid tumor treatment, starting with glioblastoma
The PLEX technology pairs with Active Pharmaceutical Ingredients (APIs) to deliver drugs at optimal release rates, ranging from days to months.
Positive
- Phase 3 clinical trial ongoing for D-PLEX100 in abdominal colorectal surgical site infections
- Proprietary PLEX technology enables controlled drug release over extended periods
- Expanding pipeline with OncoPLEX in preclinical stages for solid tumors treatment
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, PYPD gained 4.17%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, May 14, 2025 |
| Time: | 8:30 AM Eastern Time |
| Conference Call: | https://register-conf.media-server.com/register/BI326905131be34ceda978c4ff2ca7a54d |
| Webcast: | https://edge.media-server.com/mmc/p/bqgwfbps |
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com
FAQ
When will PolyPid (PYPD) release Q1 2025 earnings?
How can investors join PolyPid's (PYPD) Q1 2025 earnings call?
What is PolyPid's (PYPD) main product in clinical trials?
What is PolyPid's (PYPD) PLEX technology used for?
What new treatments is PolyPid (PYPD) developing beyond D-PLEX100?
